A post-hoc analysis of Longeveron's 49-person Phase 2a CLEAR MIND trial used free water MRI to assess neuroinflammation in Alzheimer's patients treated with laromestrocel, an allogeneic mesenchymal stem cell product. Reduced inflammatory signal in the left hippocampus and temporal-parietal cortex tracked with less atrophy, better cognitive scores, and lower plasma neurogranin. The findings are exploratory, unreviewed, and hypothesis-generating rather than confirmatory.
Key Points
- Free water MRI showed slowed neuroinflammation progression in hippocampus, p<0.001
- Lower inflammation correlated with less atrophy and improved MoCA scores
- Exploratory preprint, small sample; causation not established, product unapproved
Longevity Analysis
Inflammaging sits upstream of much age-related decline, and the proposition here is that a peripherally administered cell therapy modulates immune signaling outside the central nervous system with downstream effects on brain tissue. Imaging-derived inflammatory markers paired with synaptic blood biomarkers represent a measurable readout of a process that has long been inferred rather than observed, which matters as much for how neurodegeneration is monitored as for how it is treated. The same product's reported effects on age-related frailty suggest a shared inflammatory substrate linking cognition, vascular integrity, and physical capacity — though confirmation depends on larger controlled trials and sustained funding.
Original published by Longevity.Technology, by Kyle Umipig.